Sign in

Dave Siffringer

Research Analyst at Cantor Fitzgerald, L. P.

David Siffringer is the Senior Managing Director and Global Head of Equity Research at Cantor Fitzgerald, where he oversees the firm's global equity research initiatives with a particular focus on technology, healthcare, and other key sectors. Since joining Cantor Fitzgerald in 2019, Siffringer has led a team covering a broad range of companies such as Oramed Pharmaceuticals and has played a pivotal role in expanding the firm’s research and competitive positioning, though specific analyst performance rankings or returns are not publicly detailed. Before Cantor Fitzgerald, he held senior leadership roles at Barclays within Equities Distribution and Liquid Markets Sales from 2008 to 2017, and previously led US Cash Sales Trading and Technology Sector Trading at Lehman Brothers from 2000 to 2008, following his early trading career at Prudential Financial dating back to 1992. Siffringer holds a degree from Gettysburg College and maintains professional credentials regulated by FINRA.

Dave Siffringer's questions to HOME BANCSHARES (HOMB) leadership

Question · Q3 2025

Dave Siffringer asked about the outlook for net interest margin (NIM) and net interest income (NII) given recent and potential future rate cuts, the bank's NIM sensitivity, strategies for deposit growth in a lower-rate environment, and any credit concerns related to a potential government shutdown.

Answer

Chairman John Allison and CEO Stephen Tipton explained that Home BancShares' management reacts quickly to rate changes to maintain margin, with regional presidents actively managing deposit rates. They noted the company does not chase high deposit rates and has not seen an immediate impact from the government shutdown. President and Chief Lending Officer Kevin Hester added that deferments could be offered if necessary due to a shutdown.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts